Market Place
Sourcing Support
Alcon Completes Acquisition of Aerie Pharmaceuticals
22 Nov 2022 //
BUSINESSWIRE
Aerie Pharmaceuticals Announces New Employee Inducement Grant
15 Aug 2022 //
BUSINESSWIRE
Aerie Announces 1st Participant Dosed in COMET-3 Study of AR-15512
01 Aug 2022 //
BUSINESSWIRE
Aerie Concludes Exclusive License Agreement With Santen for Rhopressa, Rocklatan
07 Dec 2021 //
PRESS RELEASE
Aerie Announces Positive Phase 3 Topline Results for Netarsudil in Japan
12 Oct 2021 //
BUSINESSWIRE
Aerie Receives Positive CHMP Opinion for Roclanda®European Union
13 Nov 2020 //
PRESS RELEASE
Meeting highlights from the Committee for Medicinal Products for Human Use
13 Nov 2020 //
EMA
Santen and Aerie Conclude Exclusive License Agreement for Rhopressa®
27 Oct 2020 //
BUSINESSWIRE
Aerie Pharma Announces Successful Interim Data From Its Mercury 3 Clinical Trial
24 Sep 2020 //
BUSINESSWIRE
Aerie Announces U.S. FDA Approval of its Athlone Production of Rhopressa
15 Sep 2020 //
BUSINESSNEWS WIRE
Aerie Pharmaceuticals Submits Marketing Authorisation Application for Roclanda
03 Dec 2019 //
BUSINESS WIRE
Aerie’s netarsudil shows promise in Phase II trial in Japan
05 Nov 2019 //
CLINICAL TRIAL ARENA
Aerie Pharma Announces +Ve Topline Results for Netarsudil Ophh Solution in Ph 2
05 Nov 2019 //
BUSINESSWIRE
Medical Properties Trust to buy 10 hospitals for $700M
05 Nov 2019 //
SEEKINGALPHA
Xospata leads latest CHMP recommendations
21 Sep 2019 //
PHARMATIMES
EMA`s CHMP Recommends Three New Medicines
20 Sep 2019 //
RAPS
Aerie adds Vargas, once of Abbott, to medical affairs team
27 Aug 2019 //
FIERCE BIOTECH
Less than a year after Rhopressa launch, Aerie scores new glaucoma drug approval
14 Mar 2019 //
ENDPTS
Aerie Pharmaceuticals Reports Topline Result from Rhopressa® Mechanism of Action Study
15 Aug 2018 //
PRESS RELEASE
Aerie Announces Early Notification of FDA Acceptance of NDA Sub for Roclatan™
27 Jul 2018 //
PRESS RELEASE
Aerie Pharma Announces FDA Acceptance of NDA for Roclatan
23 Jul 2018 //
BUSINESSWIRE
Aerie Submits NDA to U.S. Food and Drug Administration for RoclatanTM
15 May 2018 //
PRESS RELEASE
Aerie Announces U.S. Launch of Rhopressa® (netarsudil ophthalmic solution)
30 Apr 2018 //
PRESS RELEASE
Aerie`s Announces U.S. Launch of Rhopressa® (netarsudil ophthalmic sol) 0.02%
30 Apr 2018 //
BUSINESSWIRE
FDA’s year-end approvals take annual tally to 46
02 Jan 2018 //
PMLIVE
Aerie Announces USFDA Approval Rhopressa®netarsudil ophthalmic solution 0.02%
18 Dec 2017 //
PRESS RELEASE
RHOPRESSA® for topical ophthalmic use Initial U.S. Approval: 2017
18 Dec 2017 //
PRESS RELEASE
Aerie bags early OK for its self-described blockbuster glaucoma drug Rhopressa
18 Dec 2017 //
ENDPTS
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.